Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Dicerna Pharmaceuticals
Thumbnail
May 09, 2022

Asset resuscitation fails to resuscitate Mereo

Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.

Thumbnail
November 25, 2021

Cholesterol “win” does Ionis and Pfizer a fat lot of good

Article image
Vantage logo
November 23, 2021

Arrowhead finds its target with Glaxo Nash deal

Article image
Vantage logo
November 18, 2021

Novo’s $3.3bn GalXC quest

The usually conservative group spends big on Dicerna – but others might be interested too.

Article image
Vantage logo
November 02, 2021

Centessa claims a place in the antitrypsin deficiency pipeline

But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.

Article image
Vantage logo
September 28, 2021

Biotech’s key fourth-quarter data 

Deciphera, Allakos and Uniqure are all set for important data disclosures.

Article image
Vantage logo
August 06, 2021

Dicerna can’t catch up with Alnylam

Phyox2 data back Dicerna’s nedosiran in just one type of primary hyperoxaluria, where Alnylam already has an 18-month head start.

Article image
Vantage logo
July 21, 2021

Dicerna confirms beclesiran as one to watch

Article image
Vantage logo
June 28, 2021

EASL 2021 – Arrowhead confirms promise in rare liver disease

Article image
Vantage logo
April 15, 2021

Vertex’s second try at a rare lung disorder

A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.

Article image
Vantage logo
March 25, 2021

Biotech’s important clinical data readouts

The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.